drugset / Trial / NCT05446688
A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This study is a single arm, non-randomized, open label phase 2 international, multicenter clinical trial to evaluate preliminary efficacy and safety in subjects with relapsed or refractory lymphoma.
Timeline
- Start
- 2022-09-01
- Primary completion
- 2024-03-01
- Completion
- 2024-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SAFIMESTOMIG | Monoclonal antibody | 45 mg/kg | — |